Ken Griffin Protara Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 3,800 shares of TARA stock, worth $7,904. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,800
Previous 300
1166.67%
Holding current value
$7,904
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding TARA
# of Institutions
40Shares Held
4.55MCall Options Held
102KPut Options Held
18.2K-
Opaleye Management Inc. Boston, MA2.69MShares$5.6 Million2.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA428KShares$889,4320.0% of portfolio
-
Boxer Capital, LLC San Diego, CA209KShares$435,1920.04% of portfolio
-
Ikarian Capital, LLC Dallas, TX203KShares$421,6180.11% of portfolio
-
Baker Bros. Advisors LP New York, NY200KShares$415,3150.01% of portfolio
About Protara Therapeutics, Inc.
- Ticker TARA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,267,400
- Market Cap $23.4M
- Description
- Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...